View ValuationPharmaron Beijing 향후 성장Future 기준 점검 3/6Pharmaron Beijing (는) 각각 연간 15.5% 및 13% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13.1% 로 예상됩니다.핵심 정보15.5%이익 성장률15.32%EPS 성장률Life Sciences 이익 성장17.9%매출 성장률13.0%향후 자기자본이익률13.11%애널리스트 커버리지Good마지막 업데이트08 Aug 2024최근 향후 성장 업데이트공시 • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.공시 • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.모든 업데이트 보기Recent updates공시 • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., China공시 • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.공시 • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.공시 • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026공시 • Jan 22Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing공시 • Jan 15Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing공시 • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.공시 • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026공시 • Oct 29Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd.Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design. The transaction is expected to close upon the satisfaction of customary closing conditions.공시 • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Jul 02Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공시 • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.공시 • May 29Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing China공시 • Apr 28Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy CommitteePharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM).공시 • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025공시 • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.공시 • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025공시 • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024공시 • Jun 29Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024공시 • Jun 22Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024.공시 • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.공시 • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.공시 • May 16Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing China공시 • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.공시 • Mar 30Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024공시 • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.공시 • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.공시 • Dec 29Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024이익 및 매출 성장 예측OTCPK:PHBB.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202616,4332,2641,2913,1821412/31/202514,4642,0375162,8711612/31/202412,6971,706-952,404163/31/202411,4851,4833902,969N/A12/31/202311,5381,601-1122,754N/A9/30/202311,4241,553-2142,777N/A6/30/202311,2721,575-5722,564N/A3/31/202310,8871,474-8062,255N/A1/1/202310,2661,375-8072,143N/A9/30/20229,5451,582-7072,037N/A6/30/20228,7931,682-3002,072N/A3/31/20228,0571,664-2421,977N/A12/31/20217,4441,661-352,058N/A9/30/20216,8491,423-1521,905N/A6/30/20216,2261,258-791,876N/A3/31/20215,6641,3171251,822N/A12/31/20205,1341,1723331,649N/A9/30/20204,7171,0085321,565N/A6/30/20204,3148654401,283N/A3/31/20203,9535943701,124N/A12/31/20193,757547184939N/A9/30/20193,499437146837N/A6/30/20193,274378247906N/A3/31/20193,089346230861N/A12/31/20182,908333150791N/A9/30/20182,713300-721692N/A12/31/20172,294231N/A552N/A12/31/20161,634177N/A236N/A12/31/20151,12874N/A217N/A12/31/201479021N/A12N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PHBB.F 의 연간 예상 수익 증가율(15.5%)이 saving rate(2.5%)보다 높습니다.수익 vs 시장: PHBB.F 의 연간 수익(15.5%)이 US 시장(17%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: PHBB.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: PHBB.F 의 수익(연간 13%)이 US 시장(연간 11.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: PHBB.F 의 수익(연간 13%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PHBB.F의 자본 수익률은 3년 후 13.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/11 20:59종가2024/05/14 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmaron Beijing Co., Ltd.는 24명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bo LiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.Jin ZhangChina International Capital Corporation Limited21명의 분석가 더 보기
공시 • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.
공시 • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.
공시 • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., China
공시 • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.
공시 • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.
공시 • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
공시 • Jan 22Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing
공시 • Jan 15Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing
공시 • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.
공시 • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
공시 • Oct 29Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd.Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design. The transaction is expected to close upon the satisfaction of customary closing conditions.
공시 • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Jul 02Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공시 • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.
공시 • May 29Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing China
공시 • Apr 28Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy CommitteePharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM).
공시 • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025
공시 • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.
공시 • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025
공시 • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
공시 • Jun 29Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
공시 • Jun 22Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024.
공시 • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.
공시 • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.
공시 • May 16Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing China
공시 • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.
공시 • Mar 30Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
공시 • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.
공시 • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.
공시 • Dec 29Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024